Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

DMXAA (STING agonist) efficacy on tumor microenvironment after CAR-T therapy

ABSTRACT: DMXAA (STING agonist) efficacy on tumor microenvironment after CAR-T therapy

PROVIDER: PRJNA680502 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR13125359.fastq.gz	Fastqsanger.gz
	SRR13125360.fastq.gz	Fastqsanger.gz
	SRR13125361.fastq.gz	Fastqsanger.gz
	SRR13125362.fastq.gz	Fastqsanger.gz
	SRR13125363.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 32

Similar Datasets

DMXAA (STING agonist) efficacy on tumor microenvironment after CAR-T therapy

Project description:This study is designed to uncover the mechanism by which STING agonist (DMXAA) changes the tumor microenivorment of mammary tumor to support Th/Tc17 CAR-T cells treatment.

2020-11-25 | GSE162073 | GEO

PSC co-culture STING modulation 167 samples bulk RNA-seq

Project description:Bulk RNAseq of pancreatic stellate cells (PSC) and tumour cells treated with STING agonist DMXAA, STING inhibitor H151 or DMSO control. PSC were cultured alone as mono-cultures or in co-culture with mouse tumour organoids, The PSC and tumour cells were recovered by FACS using fluorecent proteins mKate-2 and tGFP, respectively.

2025-03-19 | E-MTAB-14946 | biostudies-arrayexpress

Transcriptome-wide identification of STING agonist programed B cells

Project description:We employed RNA-seq to study the transcriptomic change in B lymphocytes in response to STING agonist. Transcriptomic analysis of wild type and TMEM173–/– B cells stimulated with STING agonist revealed that the inflammatory response pathway enriched in 3'3'-cGAMP treated WT B cells but lacking in Tmem173-/-B cells comprised of a cluster containing inhibitory regulators, provoking STING signal to evade immune surveillance by inducing an immunosuppressive B cell population.

2022-08-10 | GSE199343 | GEO

Sting

Project description:Drosophila melanogaster Sting, Sting, is differentially expressed in 23 experiment(s);

| FBgn0033453 | ExpressionAtlas

Sting

Project description:Drosophila melanogaster Sting, Sting, is expressed in 4 baseline experiment(s);

| FBgn0033453 | ExpressionAtlas

Enhancing CAR T-cell efficacy against neuroblastoma through MIF inhibition

Project description:Neuroblastoma is a common pediatric extracranial solid tumor, that arises in the developing sympathetic nervous system. Chimeric antigen receptor (CAR) T-cell therapy has demonstrated promising clinical responses, yet its effectiveness in neuroblastoma benefits only a subset of patients. We evaluated the immunosuppressive secretome of neuroblastoma tumoroids that attenuate CAR T-cells function and efficacy. Secreted proteins were collected from tumoroids and identified by shotgun MS.

2025-04-02 | PXD051044 | Pride

Neutrophil ifCAF conditioned media 18 samples bulk RNA-seq

Project description:Bone marrow-derived mouse neutrophils were cultured in vitro in conditioned media from pancreatic stellate cell (PSC) cultures where the PSCs were treated with the STING agonist DMXAA or vehicle control to induce an ifCAF phenotype.

2025-03-18 | E-MTAB-14934 | biostudies-arrayexpress

Genome-wide effect of STING-mediated activation in T cells

Project description:Using wild type mice and mice deficient for STING, we compared genome-wide expression of RNA in response to STING activation with DMXAA

2017-05-01 | GSE89361 | GEO

RNASeq analysis of solid tumours from CT26 syngeneic mice to study the role of T-cells and tumour intrinsic pathways (STING/IFN) for driving ceralasertib (AZD6738) efficacy

Project description:Understanding MoA of ceralasertib (AZD6738) in driving efficacy through immune regulation via T-cells and tumour intrinsic pathways (STING/IFN) for AZD6738 driven efficacy.

2024-01-29 | E-MTAB-13703 | biostudies-arrayexpress

NanoString immune gene expression analysis of PARP inhibitor and STING agonist treated mouse breast tumors

Project description:This study aimed to assess changes in immune gene expression and immune-related pathways in mouse tumors from syngeneic mice treated with combined PARP inhibitor and STING agonist therapy. The objective was to identify differentially expressed genes related to immune oncology in response to the combination treatment as compared to single treatments, in order to gain mechanistic insight into the enhanced anti-tumor efficacy of the combination treatment.

2022-05-29 | GSE204858 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data